Hangzhou Tigermed Consulting Valuation

Q: What is the Fair Price of 300347 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

300347 (CN¥66.08) is trading below our estimate of [[fair value]] (CN¥89.71)

Is 300347 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300347 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300347 (CN¥66.08) is trading below our estimate of fair value (CN¥89.71)

Significantly Below Fair Value: 300347 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300347?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 300347. This is calculated by dividing 300347's market cap by their current preferred multiple.
What is 300347's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

300347 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.6x
Enterprise Value/EBITDA	37.9x
PEG Ratio	1.6x

Price to Earnings Ratio vs Peers

How does 300347's PE Ratio compare to its peers?

The above table shows the PE ratio for 300347 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	51x
300759 Pharmaron Beijing	28.8x	7.0%	CN¥49.6b
603259 WuXi AppTec	20.1x	15.4%	CN¥160.6b
301333 R&G PharmaStudies	52.7x	27.8%	CN¥6.4b
688222 HitGen	102.2x	20.3%	CN¥5.4b
300347 Hangzhou Tigermed Consulting	59.4x	37.2%	CN¥53.1b

Price-To-Earnings vs Peers: 300347 is expensive based on its Price-To-Earnings Ratio (59.4x) compared to the peer average (51x).

Price to Earnings Ratio vs Industry

How does 300347's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	33.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	33.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 300347 is expensive based on its Price-To-Earnings Ratio (59.4x) compared to the Asian Life Sciences industry average (30.5x).

Price to Earnings Ratio vs Fair Ratio

What is 300347's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300347 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	59.4x
Fair PE Ratio	42.3x

Price-To-Earnings vs Fair Ratio: 300347 is expensive based on its Price-To-Earnings Ratio (59.4x) compared to the estimated Fair Price-To-Earnings Ratio (42.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300347 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥66.08	CN¥61.33 -7.2%	28.6%	CN¥85.90	CN¥32.00	n/a	17
Nov ’25	CN¥62.53	CN¥60.68 -3.0%	29.1%	CN¥85.90	CN¥32.00	n/a	16
Oct ’25	CN¥68.99	CN¥68.90 -0.1%	70.3%	CN¥248.00	CN¥33.00	n/a	16
Sep ’25	CN¥50.87	CN¥70.20 +38.0%	68.3%	CN¥248.00	CN¥33.10	n/a	16
Aug ’25	CN¥52.45	CN¥74.13 +41.3%	63.5%	CN¥248.00	CN¥35.80	n/a	16
Jul ’25	CN¥48.44	CN¥74.23 +53.2%	63.4%	CN¥248.00	CN¥35.80	n/a	16
Jun ’25	CN¥53.93	CN¥72.84 +35.1%	64.9%	CN¥248.00	CN¥35.80	n/a	16
May ’25	CN¥59.11	CN¥73.04 +23.6%	64.8%	CN¥248.00	CN¥30.90	n/a	16
Apr ’25	CN¥53.10	CN¥78.58 +48.0%	61.6%	CN¥248.00	CN¥30.90	n/a	16
Mar ’25	CN¥45.20	CN¥73.31 +62.2%	29.1%	CN¥118.92	CN¥39.60	n/a	15
Feb ’25	CN¥41.01	CN¥73.31 +78.8%	29.1%	CN¥118.92	CN¥39.60	n/a	15
Jan ’25	CN¥54.97	CN¥79.18 +44.0%	24.9%	CN¥118.92	CN¥42.00	n/a	15
Dec ’24	CN¥62.35	CN¥94.38 +51.4%	46.6%	CN¥248.00	CN¥50.90	n/a	15
Nov ’24	CN¥65.76	CN¥99.09 +50.7%	45.7%	CN¥248.00	CN¥50.90	CN¥62.53	15
Oct ’24	CN¥66.60	CN¥104.45 +56.8%	42.7%	CN¥248.00	CN¥64.00	CN¥68.99	14
Sep ’24	CN¥65.63	CN¥113.17 +72.4%	40.0%	CN¥248.00	CN¥64.00	CN¥50.87	14
Aug ’24	CN¥67.01	CN¥129.47 +93.2%	30.9%	CN¥248.00	CN¥83.00	CN¥52.45	13
Jul ’24	CN¥64.54	CN¥133.45 +106.8%	27.7%	CN¥248.00	CN¥83.00	CN¥48.44	14
Jun ’24	CN¥82.40	CN¥130.58 +58.5%	29.2%	CN¥248.00	CN¥78.46	CN¥53.93	15
May ’24	CN¥90.96	CN¥122.20 +34.3%	18.3%	CN¥155.00	CN¥78.46	CN¥59.11	14
Apr ’24	CN¥95.71	CN¥127.81 +33.5%	14.7%	CN¥155.00	CN¥83.00	CN¥53.10	13
Mar ’24	CN¥113.90	CN¥137.90 +21.1%	29.5%	CN¥260.00	CN¥82.20	CN¥45.20	14
Feb ’24	CN¥118.07	CN¥133.40 +13.0%	32.4%	CN¥260.00	CN¥82.20	CN¥41.01	14
Jan ’24	CN¥104.80	CN¥131.90 +25.9%	32.9%	CN¥260.00	CN¥82.20	CN¥54.97	14
Dec ’23	CN¥92.75	CN¥131.90 +42.2%	32.9%	CN¥260.00	CN¥82.20	CN¥62.35	14
Nov ’23	CN¥90.51	CN¥138.31 +52.8%	30.6%	CN¥260.00	CN¥82.20	CN¥65.76	14

Analyst Forecast: Target price is lower than the current share price.